Quintero-Sierra Y, Mustelier-Celza GL, Hernández-Padrón C, Romero-González A

Idioma: Español
Referencias bibliográficas: 25
Paginas:
Archivo PDF: 48.04 Kb.

RESUMEN

La leucemia mielomonocítica crónica es un desorden clonal de las células progenitoras hematopoyéticas clasificado como neoplasia mielodisplásica mieloproliferativa. Se caracteriza por la presencia de monocitosis absoluta y persistente en la sangre periférica (› 1.0 x 10 ⁹/L) con la presencia de displasia celular y mieloproliferación en la médula ósea. Los pacientes presentan síntomas relacionados a las citopenias y al estado de hipercatabolismo y al examen físico se encuentra esplenomegalia. El diagnóstico se establece con la combinación del examen de la lámina de sangre periférica, el aspirado medular y la biopsia de médula ósea, el inmunofenotipaje y el estudio molecular de las anomalías que se presentan. El pronóstico de la enfermedad es malo. El tratamiento de elección es el trasplante alogénico de progenitores hematopoyéticos con régimen de acondicionamiento de toxicidad reducida. En alrededor del 30 % de los pacientes la enfermedad se transforma en una leucemia mieloide aguda.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the classification of the acute leukaemias: French-American British (FAB) co-operative group. Br J Haematol. 1976,33:451-8.

2. Germing U, Strupp C, Knipp S, Kuendgen A, Giagounidis A, Hildebrandt B, et al. Chronic myelomonocytic leukemia in the light of the WHO proposals. Haematologica. 2007,92:974-7.

3. Parikh SA, Tefferi A. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol. 2012,87:610-9.

4. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 2009;114:937–51.

5. Sameer A, Tefferi A. Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management. Am J Hematol. 2013;88:968–74

6. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood. 2011;118:1723–35.

7. Padron E, Lee H, Wahab O. Importance of Genetics in the Clinical Management of Chronic Myelomonocytic Leukemia. J Clin Oncol. 2013;31:2428.

8. Itzykson R, Solary E. An evolutionary perspective on chronic myelomonocytic leukemia. Leukemia. 2013;27:1441–50.

9. Such E, Cervera J, Costa D, Sole F, Vallespi T, Luno E, et al. Cytogenetic risk stratification in chronic myelomonocytic leukemia. Haematologica. 2011;96:375–83.

10. Ricci C, Fermo E, Corti S, Molteni M, Faricciotti A, Cortelezzi A, et al. RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant. Clin Cancer Res. 2010;16:2246–56.

11. James C, Mazurier F, Dupont S, Chaligne R, Lamrissi-Garcia I, Tulliez M, et al. The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity. Blood. 2008;112:2429–38.

12. Kohlmann A, Grossmann V, Klein HU. Next-generation sequencing technology reveals a characteristic pattern of molecular mutations in 72.8% of chronic myelomonocytic leukemia by detecting frequent alterations in TET2, CBL, RAS, and RUNX1. J Clin Oncol. 2010;28:3858-65.

13. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gaken J, Lea NC, et al. Nextgeneration sequencing of the TET2 gene in 355 MDS and CMML patients reveals lowabundance mutant clones with early origins, but indicates no definite prognostic value. Blood, 2010;116:3923–32.

14. Jankowska A, Makishima H, Tiu R, Szpurka H, Traina F, Visconte V, et al. Mutational spectrum analysis of chronic myeilomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood, 2011;118:3932-41.

15. Germing U, Strupp C, Aivado M, Gattermann N. New prognostic parameters for myelomonocitic leukemia? Blood, 2002;100:731-3.

16. Such E, Germing U, Malcovati L, Cervera J, Kuendgen A, Della Porta MG, et al. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia. Blood, 2013;121:3005–15.

17. Itzykson R, Kosmider O, Renneville A, Gelsi-Boyer V, Meggendorfer M, Morabito M, et al. A prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol. 2013 Jul 1;31(19):2428-36. doi: 10.1200/JCO.2012.47.3314.

18. Bondar T, Medzhitov R. p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell. 2010;6:309–22.

19. Tessema M, Langer F, Dingemann J, Ganser A, Kreipe H, Lehmann U. Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia. 2003;17:910–8.

20. Takahashi K, Pemmaraju N, Strati P, Nogueras G, Ning J, Bueso C, et al. Clinical characteristics and outcomes of therapy-related chronic myelomonocitic leukemia. Blood. 2013;122:2807-11.

21. Gelsi-Boyer V, Trouplin V, Roquain J, Adelaide J, Carbuccia N, Esterni B, et al. ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia. Br J Haematol. 2010;151:365–75.

22. Itzykson R, Kosmider O, Renneville A, Morabito M, Preudhomme C, Berthon C, et al. Clonal architecture of chronic myelomonocytic leukemias. Blood. 2013;121:2186– 98.

23. Braun T, Itzykson R, Renneville A, de Renzis B, Dreyfus F, Laribi K, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. 2011;118:3824–31.

24. Cheng H, Kirtani VG, Gergis U. Current status of allogeneic HST for chronic myelomonocytic leukemia. Bone Marrow Transplant. 2012;47:535–41.

25. Itzykson R, Droin N, Solary E. Current insights in the cellular and molecular biology of chronic myelomonocytic leukemia. Int J Hematol Oncol .2012;1:147–58.